Division of Molecular Diabetes Research, Department of Diabetes, Beckman Research Institute of City of Hope, Duarte, California 91010, USA.
J Biol Chem. 2013 Aug 2;288(31):22469-80. doi: 10.1074/jbc.M113.453043. Epub 2013 Jun 20.
Glomerular hypertrophy is a hallmark of diabetic nephropathy. Akt kinase activated by transforming growth factor-β1 (TGF-β) plays an important role in glomerular mesangial hypertrophy. However, the mechanisms of Akt activation by TGF-β are not fully understood. Recently, miR-200 and its target FOG2 were reported to regulate the activity of phosphatidylinositol 3-kinase (the upstream activator of Akt) in insulin signaling. Here, we show that TGF-β activates Akt in glomerular mesangial cells by inducing miR-200b and miR-200c, both of which target FOG2, an inhibitor of phosphatidylinositol 3-kinase activation. FOG2 expression was reduced in the glomeruli of diabetic mice as well as TGF-β-treated mouse mesangial cells (MMC). FOG2 knockdown by siRNAs in MMC activated Akt and increased the protein content/cell ratio suggesting hypertrophy. A significant increase of miR-200b/c levels was detected in diabetic mouse glomeruli and TGF-β-treated MMC. Transfection of MMC with miR-200b/c mimics significantly decreased the expression of FOG2. Conversely, miR-200b/c inhibitors attenuated TGF-β-induced decrease in FOG2 expression. Furthermore, miR-200b/c mimics increased the protein content/cell ratio, whereas miR-200b/c inhibitors abrogated the TGF-β-induced increase in protein content/cell. In addition, down-regulation of FOG2 by miR-200b/c could activate not only Akt but also ERK, which was also through PI3K activation. These data suggest a new mechanism for TGF-β-induced Akt activation through FOG2 down-regulation by miR-200b/c, which can lead to glomerular mesangial hypertrophy in the progression of diabetic nephropathy.
肾小球肥大是糖尿病肾病的一个标志。转化生长因子-β1(TGF-β)激活的 Akt 激酶在肾小球系膜细胞肥大中发挥重要作用。然而,TGF-β激活 Akt 的机制尚不完全清楚。最近,miR-200 及其靶基因 FOG2 被报道可调节胰岛素信号中磷脂酰肌醇 3-激酶(Akt 的上游激活剂)的活性。在这里,我们发现 TGF-β 通过诱导 miR-200b 和 miR-200c 激活肾小球系膜细胞中的 Akt,miR-200b 和 miR-200c 均可靶向 FOG2,FOG2 是磷脂酰肌醇 3-激酶激活的抑制剂。糖尿病小鼠肾小球以及 TGF-β 处理的小鼠系膜细胞(MMC)中 FOG2 的表达减少。在 MMC 中用 siRNAs 敲低 FOG2 可激活 Akt 并增加蛋白含量/细胞比,提示发生肥大。在糖尿病小鼠肾小球和 TGF-β 处理的 MMC 中检测到 miR-200b/c 水平显著增加。MMC 转染 miR-200b/c 模拟物可显著降低 FOG2 的表达。相反,miR-200b/c 抑制剂可减弱 TGF-β 诱导的 FOG2 表达降低。此外,miR-200b/c 模拟物增加蛋白含量/细胞比,而 miR-200b/c 抑制剂则消除 TGF-β 诱导的蛋白含量/细胞比增加。此外,miR-200b/c 通过下调 FOG2 不仅可以激活 Akt,还可以激活 ERK,这也是通过 PI3K 激活的。这些数据表明,通过 miR-200b/c 下调 FOG2 可以激活 Akt 的新机制,这可能导致糖尿病肾病进展中的肾小球系膜细胞肥大。